Chennai Meenakshi Multispeciality Hospital Limited

Healthcare — Medical Care Facilities · BSE

₹36.90−₹0.12 (−0.32%)

DalalBaazaar Score

16 / 100

🔴 Poor

Verdict

HIGH RISK

Risk

Very High

Driven by negative shareholders' equity — the company owes more than it owns, short-term liabilities exceed short-term assets, the company is currently loss-making.

In simple words: The company owes more than it owns — years of losses have wiped out its net worth, but sales are shrinking. Solvency — whether it can keep funding itself at all — is the main factor to watch.

Decision support, not a buy or sell call.

As of 18 Oct 2026, 6:59 pm

Understanding the Business

Company site ↗

The 60-second version of Chennai Meenakshi Multispeciality Hospital Limited — what it does, how it earns, and who it competes with, before any of the numbers below.

What does this company do?

Chennai Meenakshi Multispeciality Hospital Limited operates a multi-specialty hospital in Chennai, India. It also sells pharmacy products.

IndustryMedical Care Facilities

SectorHealthcare

Employees223

Annual revenue₹37 Cr

How does it make money?

Turns over ₹37 Cr a year. Of every ₹100 of sales, about ₹-3 reaches shareholders as profit, with ₹3 left at the operating level before interest, tax and depreciation. Each of its 223 employees supports ₹16.5 lakh of revenue a year, the signature of a people-led business.

Revenue / employee₹16.5 lakh

Who are its competitors?

The closest listed comparisons in its industry are APOLLO HOSPITALS ENTER. L, SUN PHARMACEUTICAL IND L, CIPLA LTD. These are the companies its valuation and returns are measured against elsewhere in this report.

Compared side by side in Peers ↓

What is its competitive advantage?Little sign of one

Returns on capital of -4.5% are at or below what the capital likely costs. That is the financial pattern of a business competing largely on price, where advantage has to come from execution rather than position.

Peer median ROE14.5%

What has been driving growth?

Profit has moved mainly because margins changed, not because the business sold much more. Over 3 years revenue moved -4% while net margin moved -231% relative to itself. What this cannot tell you is which products, customers or geographies did the work — that lives in the segment disclosures of the annual report.

Revenue effect-4%

Margin effect-231%

DalalBaazaar Score

16/ 100

Poor

Weighted across six categories. Every point is explained below.

✗ Shareholders' equity is negative — accumulated losses exceed the capital in the business

Quality vs. Valuation

Company Quality

15/ 100

Weak

How good the business is, ignoring the share price entirely.

Valuation

30/ 100

Expensive

What you are being asked to pay, ignoring how good the business is.

Weak on business quality and not cheap enough to compensate.

vs. its own history

Not enough price and earnings history

vs. sector peers

Not enough peers with a usable P/E

vs. generic bands

N/A

Multiples unreliable — equity base is negative

EV/EBITDA

35.9x

PEG

—

Red Flags

6 items require attention · 5 high · 1 watch

🔴Negative shareholders' equityFinancial
Liabilities exceed assets — accumulated losses have wiped out the company's net worth.
🔴Thin interest coverageFinancial
Operating profit covers interest only -0.5x — little room if earnings dip.
🔴Profit up while operating cash flow fallsFinancial
Reported profit rose but cash generated by operations declined — worth checking whether earnings are being supported by non-cash items or working capital.
🔴The company is lossmakingFinancial
Net profit of -₹1 Cr in the latest reported year.
🔴Significant margin compressionFinancial
EBITDA margin has fallen 5.6 points, from 8.5% to 2.8%.
🟡Short-term liquidity is tightFinancial
Current ratio of 0.67 — near-term obligations exceed near-term assets.

Investment Thesis

🟢 Bull CaseWhat could make this work?

No clear supporting case emerges from the available numbers.

🔴 Bear CaseWhat could go wrong?

Solvency comes before everything else
Liabilities exceed assets. Until net worth is rebuilt, the equity is a claim on a business that owes more than it owns, and further losses or a funding squeeze can leave shareholders with nothing.
Margins are being competed away
EBITDA margin has fallen from 8.5% to 2.8%. If the trend continues, profit falls even on flat sales — and margin decline rarely reverses quickly.
The debt load needs earnings to hold up
Debt is 10.2x EBITDA. At that level a downturn in earnings turns a manageable balance sheet into a refinancing problem, and lenders get paid before shareholders.
Earnings are hard to forecast
Profit has swung sharply from year to year, so any single year — good or bad — is a weak guide to the next. Cyclical earnings deserve lower multiples for that reason.
Size brings its own risk
Micro Cap businesses are thinly traded, so exits are harder in a falling market and single events move the price more than they would for a larger company.

🟡 Key Things to WatchMeasurable tripwires, set against where this company stands today

1EBITDA margin holds above 1%✓ 2.8%
Two points below today's level — enough room for noise, tight enough to catch real compression.
2Debt / EBITDA falls below 3x✗ 10.2x
Already stretched, so this is a reduction target rather than a level to hold. Around 3x is where lenders typically start attaching conditions.
3Interest cover stays above 3x✗ -0.5x
How much operating profit can fall before interest stops being comfortably covered.
4Free cash flow remains positive✓ ₹0 Cr
Profit that never becomes cash eventually stops being profit.

Investment Checklist

4 / 10 checks passed

✗ Shareholders' equity is positive (assets exceed liabilities)
✗ Strong return on capital employed (ROCE ≥ 15%)
✗ Healthy net margin (≥ 10%)
✓ Generates positive free cash flow
✗ Adequate short-term liquidity (Current Ratio ≥ 1.0)
✗ Revenue growing year-over-year
✓ Profit growing year-over-year
✓ Not trading at an extreme valuation (P/E < 40x)
✓ Not buying right at the 52-week high
✗ Short-term technical trend isn't bearish

Price history

Quick Metrics

2 good · 4 neutral · 5 weak

Market Cap

₹28 Cr

Micro Cap

Smaller company — thin liquidity and deep drawdowns are normal here

P/E (Trailing)

Not meaningful

Loss-making

Earnings are negative, so a P/E multiple can't be read here

P/B Ratio

Not available

No data

Source didn't return this field

EPS (TTM)

₹-0.55

Loss-making

Negative earnings per share — the business is losing money

ROE

Not meaningful

Negative equity

Return on equity can't be read when equity itself is negative

ROCE

-4.5%

Distorted

Distorted by the negative net worth — read this alongside the solvency flag, not on its own

Debt/Equity

Not meaningful

Negative equity

Shareholders' equity is negative, so this ratio can't be read

Revenue Growth (YoY)

-0.7%

Shrinking

Sales are contracting

Profit Growth (YoY)

18.7%

Healthy

Profits growing at a healthy clip

Dividend Yield

None

No dividend yield reported — usually means no payout, but verify if one was recently initiated

Free Cash Flow

₹0 Cr

Cash generative

Generates cash even after funding its capex

More Metrics

Operating Margin

1.1%

Weak

Thin margins leave little room for error

Net Margin

-1.0%

Weak

Very little revenue reaches the bottom line

Current Ratio

0.67

Tight

Tight short-term liquidity

Beta (vs Nifty)

0.43

Defensive

Steadier than the market

52W Range Position

21%

Mid-range

Technical Snapshot

SMA 20 / SMA 50

37.8 / 38.0

Bearish alignment (short < long)

Price vs SMA 200

Below

Long-term downtrend

RSI (14)

40.9

Neutral momentum

Financial Trend (4-Year)

Metric	FY23	FY24	FY25	FY26	3Y CAGR
Revenue	₹39 Cr	₹38 Cr	₹35 Cr	₹37 Cr	-1.5%
EBITDA	₹3 Cr	₹2 Cr	₹1 Cr	₹1 Cr	-31.6%
EBITDA Margin	8.5%	5.8%	1.5%	2.8%	—
PAT (Net Profit)	₹1 Cr	-₹0 Cr	-₹1 Cr	-₹1 Cr	—
EPS	₹1.19	₹-0.57	₹-1.84	₹-1.5	—
ROCE	17.3%	7.1%	-6.4%	-4.5%	—
Total Debt	₹11 Cr	₹11 Cr	₹11 Cr	₹11 Cr	+0.0%
Free Cash Flow	₹2 Cr	-₹0 Cr	₹2 Cr	₹0 Cr	-47.6%

🟡 Revenue has been broadly flat over 3 years (-1.5% a year).

🔴 EBITDA has shrunk at 31.6% a year over 3 years.

🔴 EBITDA Margin has fallen from 8.5% to 2.8% over 3 years (-5.6 pts).

🔴 PAT (Net Profit) has turned negative, from ₹1 Cr to -₹1 Cr.

🔴 EPS has turned negative, from ₹1.19 to ₹-1.5.

🔴 ROCE has fallen from 17.3% to -4.5% over 3 years (-21.8 pts).

🟡 Total Debt has been broadly flat over 3 years (0.0% a year).

🔴 Free Cash Flow has shrunk at 47.6% a year over 3 years.

Balance Sheet & Cash Flow — FY2026

Total Assets

₹21 Cr

Total Liabilities

₹24 Cr

Cash & Equivalents

₹1 Cr

Operating Cash Flow

₹0 Cr

Capex

-₹0 Cr

Shareholding (proxy)

Institutional Holding

0.0%

Insider Holding

64.7%

Corporate Actions

Ex-Dividend Date

15 Oct 2001

Peer Comparison

Company	P/E	ROE
APOLLO HOSPITALS ENTER. L	54.3x	22.0%
SUN PHARMACEUTICAL IND L	34.9x	14.5%
CIPLA LTD	31.8x	9.8%

Recent News

1 positive1 negative4 general

Chennai Meenakshi Multispeciality Hospital Ltd. Shareholding Pattern – Promoters, FIIs & DIIs

Value Research, 29 Aug

Chennai Meenakshi Multispeciality board meeting rescheduled to September 1

scanx.trade, 22 Aug

Chennai Meenakshi CEO resigns effective June 15, 2026

scanx.trade, 15 JunManagement

🔴Potentially negativeA senior departure, and an auditor's resignation especially, is worth understanding before anything else in this report.

Cubical Financial Services standalone net profit rises 228.57% in the June 2026 quarter

Business Standard, 11 AugResults

🟢Potentially positiveReported improvement. Check whether it came from volume, price or a one-off item before treating it as a trend.

Chennai Meenakshi Hospital sets Sept 30 AGM; book closure starts Sept 24

scanx.trade, 01 Sept

Chennai Meenakshi Multispeciality Hospital Limited (523489) Company Information

Simply Wall Street, 09 Aug

Watch Items

Revenue growth is negative (-0.7%) on the latest reported period — check if this is one-off or a trend.
Cross-check against the company's latest quarterly filing / investor presentation before acting.
1 metric couldn't be retrieved for this stock — this is more common for smaller or thinly-covered listings.

DalalBaazaar Thesis

WeakBusiness Quality · Financial Health · Growth · Profitability · Valuation · Risk

Points for each in the Score ↑

Avoid until solvency is resolved

Chennai Meenakshi Multispeciality Hospital Limited owes more than it owns. Whatever the operating numbers show, the equity is a residual claim on a business with negative net worth, and that question has to be settled before any of the rest is worth weighing. 5 high-severity red flags sit above this conclusion and should be read first.

2 of 4 tripwires tripped — Debt / EBITDA falls below 3x; Interest cover stays above 3x · see Key things to watch ↑